ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 564

Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)

Katie Tuckwell1, Cem Gabay2, Thierry Sornasse1, Ruediger Laubender3, Jianmei Wang4 and Michael Townsend1, 1Genentech, Inc., South San Francisco, CA, 2University Hospitals of Geneva, Geneva, Switzerland, 3Roche Diagnostics, Penzberg, Germany, 4Roche Products Ltd., Welwyn Garden City, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologics, biomarkers and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The biomarkers CXCL13 and sICAM1 have been associated with outcomes in patients with RA treated with TCZ. This study evaluated the association of CXCL13 and sICAM1 with disease activity and response to TCZ in early RA and DMARD-IR patients.

Methods: Patient subsets from the FUNCTION (early RA) and LITHE (DMARD-IR) clinical trials were selected based on baseline and Week 24 sample availability; serum CXCL13 and sICAM1 levels were measured. Correlations between CXCL13 and sICAM1 levels and DAS28-ESR at baseline, and between change in CXCL13 and sICAM1 levels and change in DAS28-ESR at Week 24, were determined. Changes in CXCL13 and sICAM1 levels from baseline to Week 24 were compared between treatment arms using Welch t test. The effect of treatment, baseline DAS28-ESR and baseline CXCL13 and sICAM1 levels on the likelihood of DAS28-ESR remission and ACR50 response at Week 24 was determined via logistic regression. DAS28-ESR remission and ACR50 rates were compared against CXCL13 and sICAM1 status (high vs low median values) within each trial arm using a Cochran-Mantel-Haenszel test.

Results: Overall, 458 of 872 patients from FUNCTION (TCZ + MTX, n = 160; TCZ monotherapy [TCZ-mono], n = 157; placebo [PBO] + MTX, n = 141) and 287 of 791 patients from LITHE (TCZ + MTX, n = 137; PBO + MTX, n = 150) were included. In these patient subsets, mean disease duration in FUNCTION was significantly shorter than in LITHE (0.45 vs 8.65 years). At baseline, correlation of serum CXCL13 levels with DAS28-ESR was moderate in the early RA population and weak in the DMARD-IR population (Table). Correlation between baseline serum sICAM1 levels and DAS28-ESR was low in both populations. Serum levels of CXCL13 decreased significantly at Week 24 in all treatment arms in both populations; sICAM1 levels decreased significantly at Week 24 in the TCZ-mono arm in patients with early RA and the TCZ + MTX arms in both populations but not in the PBO + MTX arms. Change in CXCL13 levels correlated moderately with change in DAS28-ESR at Week 24 in both populations (Table). Change in sICAM1 levels correlated moderately with change in DAS28-ESR at Week 24 in the DMARD-IR population but weakly in the early RA population. Although the treatment arm had a significant effect on the likelihood of DAS28-ESR remission and achievement of ACR50, the effect of baseline levels of CXCL13 and sICAM1 were not significant. DAS28-ESR remission and ACR50 response rates at Week 24 within each treatment arm of the early RA and DMARD-IR populations were not significantly different between patients with high vs low baseline CXCL13 and sICAM1 levels.

Conclusion: The association of baseline CXCL13 levels with RA disease activity was stronger in the early RA population than in the DMARD-IR population. Baseline levels of CXCL13 and sICAM1 did not predict response to TCZ at Week 24, suggesting that although these biomarkers are associated with disease activity, they do not predict response to TCZ in all RA populations.

 

Table. Correlation Between Serum CXCL13 and sICAM1 Levels and DAS28-ESR

 

Baseline

Week 24*

CXCL13

sICAM1

Δ CXCL13

Δ sICAM1

n

r

P value

n

r

P value

n

r

P value

n

r

P value

FUNCTION

(early RA)

458

0.36

< 0.0001

458

0.14

0.0029

458

0.33

< 0.0001

458

0.16

0.0005

LITHE

(DMARD-IR)

282

0.21

0.0003

282

0.17

0.0040

202

0.33

< 0.0001

202

0.26

0.0002

CXCL13, C-X-C motif chemokine ligand 13; DAS28-ESR, Disease Activity Score in 28 joints per erythrocyte sedimentation rate; DMARD-IR, inadequate response to disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; sICAM1, soluble intercellular adhesion molecule 1.

* Correlation between change in CXCL13 and sICAM1 levels from baseline to Week 24 and change in DAS28-ESR from baseline to Week 24; all patients combined.

 


Disclosure: K. Tuckwell, Genentech, Inc., 3; C. Gabay, AB2 Bio, Pfizer and Roche, 2,AB2 Bio, AbbVie, Bristol Myers Squibb, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, UCB, 5, 8; T. Sornasse, Genentech, Inc., 3; R. Laubender, Roche Diagnostics, 3; J. Wang, Roche Products Ltd., 3; M. Townsend, Genentech, Inc., 3.

To cite this abstract in AMA style:

Tuckwell K, Gabay C, Sornasse T, Laubender R, Wang J, Townsend M. Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/levels-of-cxcl13-and-sicam1-correlate-with-disease-activity-score-in-rheumatoid-arthritis-ra-patients-treated-with-tocilizumab-tcz/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/levels-of-cxcl13-and-sicam1-correlate-with-disease-activity-score-in-rheumatoid-arthritis-ra-patients-treated-with-tocilizumab-tcz/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences